1Herskovic A, Sauraf MA. Contribution of 5-fluorouracial and radiation oncology in esophageal cancer[ J]. Sernin Rad Oncol, 1997,4:283.
2Misset JL. Oxaliplatin in practice [ J]. Br J Cancer, 1998,77 ( Suppl 4) :4.
3Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouraeil and radiation:report of a clinical trial for patients with esophageal cancer[ J]. J Clin Oncol,2002, 20(12) :2844.
5Degramant A,Louvet C, AndreT, et al. A review of GERCOD trials of bimonthly leucovorin pluse 5-Fluorrouracil 48-hour continuous onfusion in advanced colorectal cancer: evalution of a regimen [ J]. Eur J Cancer, 1998,34(5 ) :619.
6Goldberg RM, Sargent D J, Morton RF, et al. A randomized controlled trial of fluorouraeil plus leucovorin, irirotecan, and oxaliplatin combinations in patients with previously untreated metastasis colorectal cancer [ J]. J Clin Oncol,2004,22 ( 1 ) :23.
7Ilson DH, Saltz L, Enxinger P, et al. Phase Ⅱ trial of weekly irinotecan pluse cisplatin in advanced esophageal cancer[J]. Clin Oncol, 1999, 17(10) :3270.
二级参考文献5
1Roth JA, Lichter AS, Putnam JB, et al. Cancer of the esophus [ A]. de Vita VT, Hellman SA. Principles and practice of oncology [ M]. 6^th ed, Lippincott : philadelphia, 1993 : 776 - 817.
2Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5 - fluorouraoil selectively in tumors by enzymes concentrated in human liver and cancer tissue[J]. Eur J Cancer Clin Oncol, 1998,34(8) : 1274 - 1281.
3Muro K, Hamaguchi T, Ohtsu A, et al. A phase lI study of singer - agent docetaxel in patients with metastatic esophageal cancer [J]. Ann Onc, 2004, 15(6) : 955 -959.
4Hirao M, Fujitani K, Tsujinaka T. Phase I study of the combination of nedaplatin, adriamycin and 5 - fluorouracil for. treatment of advanced esophageal cancer[ J]. Dis Esophagus, Pub Med,2004, 17(3) :247 -250.
